August 03, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: **526783**

Dear Sir / Madam,

Subject: Outcome of the Board meeting held on August 03, 2026

In continuation of our letter dated July 28, 2026, regarding the captioned subject and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, August 03, 2026, has *inter alia*, considered and approved:

A. Unaudited Financial Results of the Company for the quarter ended June 30, 2026

Pursuant to Regulation 33 of the SEBI Listing Regulations, the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 ("Financial Results"), along with the Limited Review Report issued by the Statutory Auditors of the Company are enclosed.

Further, the Financial Results shall be published in the newspapers in compliance with Regulation 47 of the SEBI Listing Regulations and the same will also be available on the website of the Company at www.dragarwals.co.in.

B. Re-appointment of M/s. B Y & Associates, Practicing Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27

In accordance with the provisions of Section 148 of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Rules, 2014, and as recommended by the Audit Committee, M/s. B Y & Associates, Practicing Cost Accountants, (Firm Registration No. 003498) were re-appointed as the Cost Auditors to conduct the audit of the Cost Records of the Company for the financial year 2026-27.

The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the aforesaid re-appointment of Cost Auditor are enclosed herewith as Annexure I.

The meeting commenced at 03:00 P.M. IST and concluded at 03:45 P.M. IST.

Kindly take the above information on record.

For **Dr. Agarwal's Eye Hospital Limited**

Meenakshi Jayaraman

Digitally signed by Meenakshi Jayaraman
Date: 2026.08.03 17:22:10 +05'30'

Meenakshi Jayaraman
Company Secretary and Compliance Officer

Encl.: as above

S.R. BATLIBOI & ASSOCIATES LLP
Chartered Accountants

10th Floor, Tidel Park
"A" Block, North Wing
No. 4, Rajiv Gandhi Salai
Taramani, Chennai - 600 113 India

Tel: +91 44 6117 9000

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Dr. Agarwal's Eye Hospital Limited

1. We have reviewed the accompanying statement of unaudited financial results of Dr. Agarwal's Eye Hospital Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S.R. Batliboi & Associates LLP
Chennai
Chartered Accountants

5. The comparative unaudited Ind AS financial information of the Company for the corresponding quarter ended June 30, 2025, included in these unaudited Ind AS financial results, were reviewed by the predecessor auditor who expressed an unmodified conclusion on those unaudited Ind AS financial information on August 12, 2025.

For **S.R. Batliboi & Associates LLP**
Chartered Accountants
ICAI Firm registration number: 1011049W/E300004

Aravind.K

per Aravind K
Partner
Membership No.: 221268
Chennai, Tamil Nadu
August 03, 2026
UDIN: 26221268TPGDLC9581

S.R. Batliboi & Associates LLP
Chennai
Chartered Accountants

Dr. Agarwal's Eye Hospital Limited
CIN : L85110TN1994PLC027366
Regd Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Dr Agarwals Eye Hospital

(Amounts in INR Crores except EPS)

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2026

S.No.	Particulars	Quarter Ended			Year Ended
		30-Jun-26 Unaudited	31-Mar-26 Audited (Refer Note 4)	30-Jun-25 Unaudited (Refer Note 3)	31-Mar-26 Audited
1	**Income**				
	(a) Revenue from operations	142.97	120.01	116.92	470.87
	(b) Other income	1.96	1.57	0.80	5.82
	Total income	**144.93**	**121.58**	**117.72**	**476.69**
2	**Expenses**				
	(a) Purchase of stock-in-trade	14.66	12.03	11.87	47.73
	(b) Changes in inventories of stock-in-trade - (increase) / decrease	(1.06)	(0.90)	0.38	(0.71)
	(c) Consumption of surgical lens including other consumables	16.55	13.84	13.89	54.44
	(d) Consultancy charges for doctors	19.66	16.04	15.39	61.44
	(e) Employee benefits expense	27.48	23.96	22.18	91.68
	(f) Finance costs	2.77	1.96	4.16	11.88
	(g) Depreciation and amortisation expense	11.49	12.09	10.58	45.64
	(h) Other expenses	22.42	21.31	16.08	70.98
	Total expenses	**113.97**	**100.33**	**94.53**	**383.08**
3	**Profit before tax (1-2)**	**30.96**	**21.25**	**23.19**	**93.61**
	Tax expense				
	- Current tax (including tax pertaining to earlier periods)	7.67	4.89	5.92	23.47
	- Deferred tax (net)	(0.09)	0.12	0.01	0.04
4	**Total tax expense**	**7.58**	**5.01**	**5.93**	**23.51**
5	**Net profit after tax for the period (3-4)**	**23.38**	**16.24**	**17.26**	**70.10**
6	**Other comprehensive income/ (loss)**				
	Items that will not be reclassified to the statement of profit and loss				
	-Re-measurement gains/ (losses) on defined benefit plans	(0.63)	0.19	0.06	0.03
	- Tax on items that will not be reclassified to the statement of profit and loss	0.16	(0.05)	(0.02)	(0.01)
	Total other comprehensive income/ (loss) (net of tax)	**(0.47)**	**0.14**	**0.04**	**0.02**
7	**Total comprehensive income (5+6)**	**22.91**	**16.38**	**17.30**	**70.12**
8	Paid-up equity share capital (Face value INR 10/- each)	4.83	4.83	4.70	4.83
9	Reserves (other equity)				341.47
10	**Earnings per equity share (EPS) (Face value of INR 10/- each)**				
	(a) Basic	48.38	33.60	36.72	147.02
	(b) Diluted	48.38	33.60	36.72	147.02
		(not annualised)	(not annualised)	(not annualised)	
	Additional Information:				
	Earnings before Finance cost, Depreciation, amortisation and Tax (EBITDA) (Refer Foot Notes)	45.22	35.30	37.93	151.13

See accompanying notes to the unaudited financial results.

Foot note:

(i) The company has presented information on EBITDA additionally as a part of the statement of financial results as defined below.
(ii) EBITDA= Profit before tax + Depreciation and amortisation expense + Finance costs

FOR IDENTIFICATION PURPOSES ONLY S.R. BATLIBOI & ASSOCIATES LLP CHARTERED ACCOUNTANTS CHENNAI

Dr. Agarwal's Eye Hospital Ltd. Chennai

By order of the Board

Place : Chennai

Date: August 03, 2026

Dr. Amar Agarwal
Chairman & Managing Director
DIN: 00435684

Dr. Agarwal's Eye Hospital Limited
Dr Agarwals Eye Hospital
CIN : L85110TN1994PLC027366
Regd Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2026

Notes:

1 These unaudited financial results have been prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and Regulation 33, issued by the Securities and Exchange Board of India (SEBI) under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

2 The above unaudited financial results have been reviewed by the Audit Committee and approved and taken on record by the Board of Directors in their respective meetings held on August 03, 2026. The said results for the quarter ended June 30, 2026 has also been subjected to limited review by M/s S.R. Batliboi & Associates LLP, the Statutory Auditors of Dr. Agarwal's Eye Hospital Limited ("AEHL" or "the Company").

3 The corresponding unaudited financial results for the quarter ended June 30, 2025, were reviewed by the predecessor Statutory Auditors of the Company.

4 The comparative financial results for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of the financial year ended March 31, 2026, and the unaudited year-to-date figures for the nine months ended December 31, 2025, which were subjected to a limited review by the Statutory Auditors.

5 The Company operates in a single segment i.e., "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 – Operating Segments.

6 The Board of Directors of the Company, at its meeting held on August 27, 2025, approved the proposed scheme of amalgamation ("Scheme") with its Holding Company, Dr. Agarwal's Health Care Limited ("AHCL"). Pursuant to the order of the Hon'ble NCLT, Chennai Bench, dated May 05, 2026, the meetings of the equity shareholders, secured creditors and unsecured creditors of both the companies were held on July 02, 2026. The resolutions for approval of the Scheme were duly approved by the requisite majority of the equity shareholders, secured creditors and unsecured creditors of AEHL and AHCL and were deemed to be passed on July 02, 2026. The Scheme remains subject to final sanction of the Hon'ble NCLT and completion of other applicable statutory / regulatory requirements.

7 The Board of Directors of the Company, at its meeting held on August 27, 2025, approved the issuance of 1,32,827 equity shares of the Company having face value of INR 10 each at a price of INR 5,270 per share by way of Preferential issue amounting to INR 70 crores to Dr. Agarwal's Health Care Limited. This was approved by the shareholders in its Annual General Meeting held on September 24, 2025 and the relevant shares were allotted on September 26, 2025. The Company has received the listing and trading approvals from the stock exchange on October 16, 2025 and October 28, 2025, respectively. The Company has utilised INR 28.20 crores of the proceeds of preferential allotment as per the terms of objects which were approved by the shareholders and the balance unutilised portion as at June 30, 2026 have been temporarily invested in debt mutual funds by the Company.

8 The Company does not have any subsidiary / associate / joint venture entity for the quarter ended June 30, 2026.

FOR IDENTIFICATION PURPOSES ONLY
S.R. BATLIBOI & ASSOCIATES LLP
CHENNAI
CHARTERED ACCOUNTANTS

Dr. Agarwal's Eye Hospital Ltd.
Chennai

By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN: 00435684

Place : Chennai
Date: August 03, 2026

Dr Agarwals
Eye Hospital

Dr. Agarwal's Eye Hospital Limited
CIN : L85110TN1994PLC027366
Regd Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018
Phone No. 91-44-43787777 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in INR Crores)

Statement of Unaudited Financial Results for the Quarter ended June 30, 2026

Particulars	Quarter Ended			Year ended
	30-Jun-26 (Unaudited)	31-Mar-26 Audited (Refer Note 2)	30-Jun-25 (Unaudited) (Refer Note 3)	31-Mar-26 Audited
Revenue from Operations	142.97	120.01	116.92	470.87
Net Profit for the period before Tax	30.96	21.25	23.19	93.61
Net Profit for the period after tax	23.38	16.24	17.26	70.10
Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income/Loss (after tax)]	22.91	16.38	17.30	70.12
Paid-up Equity Share Capital (Face Value of INR 10/- each)	4.83	4.83	4.70	4.83
Reserves (Other Equity)				341.47
Earnings Per Share (Face Value of INR 10/- each):				
(a) Basic	48.38	33.60	36.72	147.02
(b) Diluted	48.38	33.60	36.72	147.02
	(not Annualised)	(not Annualised)	(not Annualised)	

Notes:

1) The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).

2)The comparative financial results for the quarter ended March 31, 2026, are the balancing figures between the audited figures in respect of the financial year ended March 31, 2026, and the unaudited year-to-date figures for the nine months ended December 31, 2025, which were subjected to a limited review by M/s S.R. Batliboi & Associates LLP, the Statutory Auditors of Dr. Agarwal's Eye Hospital Limited .

3)The corresponding unaudited financial results for the quarter ended June 30, 2025, were reviewed by the predecessor Statutory Auditors of the Company.

By order of the Board

Dr. Agarwal's Eye Hospital Ltd. Chennai

Place : Chennai
Date : 03 August 2026

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

ANNEXURE I

Re-appointment of M/s. B Y & Associates, Practicing Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	In accordance with the provisions of Section 148 of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Rules, 2014, and as recommended by the Audit Committee, M/s. B Y & Associates, Practicing Cost Accountants, (Firm Registration No. 003498) were re-appointed as the Cost Auditors to conduct the audit of the Cost Records of the Company for the financial year 2026-27.
2.	Date of ~~appointment/~~ re-appointment/~~cessation (as applicable) &~~ term of ~~appointment/~~re-appointment	August 03, 2026. M/s. B Y & Associates, Practicing Cost Accountants, shall hold office as the Cost Auditors, to conduct the audit of the Cost Records of the Company, till the expiry of (i) one hundred and eighty days from the closure of the financial year 2026-27 or (ii) till he submits the cost audit report for the financial year 2026-27, whichever is earlier.
3.	Brief profile (in case of appointment)	N.A.
4.	Disclosure of relationships between directors (in case of appointment of a director).	N.A.